3D genome architecture and epigenetic regulation of lineage identity in advanced prostate cancer
Endocrinology · 26.05.2026 · 167 (7)
DOI: 10.1210/endocr/bqag068 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Endocrinology, online erschienen am 17.06.2026. Verfasst von Songyan Qi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA. Hauptthemen laut MEDLINE: Epigenesis, Genetic, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant, Genome. Die Arbeit nennt 87 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Prostate cancer development and progression depend on androgen receptor (AR) signaling. Therefore, androgen-deprivation therapy (ADT) and AR signaling inhibitors (ARSIs) are standard therapies for advanced or metastatic disease. Although these treatments are initially effective, prostate cancer inevitably progresses to a lethal stage termed castration-resistant prostate cancer (CRPC). In the majority of patients, CRPC occurs via reactivation of AR signaling (CRPC-AR). However, lineage plasticity is a hallmark of cancer that drives AR-independent CRPC phenotypes in a subset of patients. One subtype of AR-negative CRPC is neuroendocrine prostate cancer (NEPC), which transforms from CRPC-AR by losing the characteristic AR-driven luminal epithelial identity and gaining neuroendocrine identity. Another AR-negative CRPC subtype lacks AR and neuroendocrine features and has therefore been classified as double-negative prostate cancer (DNPC). Chromatin modifications, alterations in three-dimensional (3D) genome structure, and expression of transcriptional regulators are crucial for controlling lineage states and modulating AR-dependent and AR-independent phenotypes in CRPC. Here, we highlight how high-resolution investigations of the 3D genome have revealed interdependence between chromatin architecture and transcriptional regulation, offering novel insights into the mechanisms of CRPC progression and context-specific targets for therapeutic intervention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.
- Graduate Program in Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN 55455, USA.
- Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN 55455, USA.
- Department of Urology, University of Minnesota, Minneapolis, MN 55455, USA.
ORCID-Profile: Scott M Dehm
Förderung
- NCI NIH HHS
- National Cancer Institute
Zitieren
APA
Qi, S., & Dehm, S. M. (2026). 3D genome architecture and epigenetic regulation of lineage identity in advanced prostate cancer. Endocrinology, 167(7). https://doi.org/10.1210/endocr/bqag068
Vancouver
Qi S, Dehm SM. 3D genome architecture and epigenetic regulation of lineage identity in advanced prostate cancer. Endocrinology. 2026;167(7). doi:10.1210/endocr/bqag068
BibTeX
@article{Qi2026,
author = {Qi, Songyan and Dehm, Scott M},
title = {3D genome architecture and epigenetic regulation of lineage identity in advanced prostate cancer},
journal = {Endocrinology},
year = {2026},
volume = {167},
number = {7},
doi = {10.1210/endocr/bqag068}
}
EUVIMED